



DAVID COOPER SYMPOSIUM

TREATMENT AND PREVENTION ACCESS FOR ALL

Friday 15 June 2018

Science Theatre, Kensington Campus, UNSW Sydney

SYMPOSIUM OPENING

Chairs:
Professor John Kaldor,
Professor Anthony
Kelleher

8:00am	Registration
9:00am	Welcome to Country
9:05am	Welcome Professor Ian Jacobs, President and Vice-Chancellor, UNSW Sydney
9:10am	Opening Senator the Hon Lisa Singh, Co-chair of the Parliamentary Group on HIV/AIDS and Blood-borne Viruses
9:20am	Video message The Hon Greg Hunt, Minister for Health
9:25am	From molecules to populations Professor Anthony Kelleher
9:40am	Special Presentation
9:50am	Brett Tindall Lecture: Ending AIDS in Thailand Professor Emeritus Praphan Phanuphak
10:20am	Adult and paediatric infectious diseases clinical trial networks in Africa - challenges, impact, future directions Dr Sarah Pett
10:35am	Morning Tea

SESSION 2

Chairs:
Mr Bill Bowtell,
Associate Professor
Allison Imrie

11:00am	The role of research in global health H. Clifford Lane M.D.
11:30am	A HIV test and treat initiative in Indonesia: the HATI project Professor Matthew Law
11:45am	Building laboratory support for translational research in our region Associate Professor Philip Cunningham
12:00pm	A reflection on community engagement with HIV research Ms Jo Watson
12:15pm	Lunch

SESSION 3

Chairs:
Professor Janaki Amin,
Dr Mark Polizzotto

1:05pm	AIDS is (STILL) political Professor Linda-Gail Bekker
1:35pm	HIV and ageing: a long journey Professor Brian Gazzard
2:05pm	Coops, co-morbidities and the pursuit of safe, lifelong therapy for HIV Dr Patrick Mallon
2:20pm	The evolving role of molecular epidemiology in HIV prevention Dr Angie Pinto
2:35pm	The role of an HIV cure in moving towards HIV elimination Professor Sharon Lewin
2:50pm	Afternoon Tea
3:15pm	EPIC-NSW

SESSION 4

Chairs:
Professor Rebecca
Guy, The Hon Jillian
Skinner

	<ul style="list-style-type: none"> • The role of government Dr Kerry Chant • Education and mobilisation Ms Karen Price • Early results and challenges for the future Professor Andrew Grulich
3:45pm	Vaccination to prevent sexually transmitted infection: What's on the horizon? Professor Basil Donovan
4:00pm	Striving towards HCV elimination in Australia: current progress, future challenges Associate Professor Gail Matthews
4:15pm	Panel discussion: HIV elimination - what does it look like, and when will we get there? Facilitated by: Dr Bridget Haire Panel: Professor Linda-Gail Bekker, Dr Kerry Chant, Mr Geoff Honnor, H. Clifford Lane M.D., Professor Emeritus Praphan Phanuphak, Professor Carla Treloar
5:00pm	Close and thanks Professor Anthony Kelleher
5:00pm - 6:00pm	Cocktail Reception

#DACSymposium

Professor Linda-Gail Bekker



Deputy Director, The Desmond Tutu HIV Centre, University of Cape Town, South Africa; President, International AIDS Society

Linda-Gail Bekker is a Professor of Medicine, the Deputy Director of the Desmond Tutu HIV Centre and Chief Operating Officer of the Desmond Tutu HIV Foundation. She is President of the International AIDS Society (2016–2018). She has been involved in the South African

AIDS response since the late 90s and conducts health service and clinical research in HIV, tuberculosis and related topics.

Associate Professor Philip Cunningham



Chief Operating Officer, St Vincent's Centre for Applied Medical Research and NSW State Reference Laboratory for HIV, St Vincent's Hospital Sydney Australia

Philip Cunningham directs the NSW State Reference Laboratory for HIV at St Vincent's Hospital in Sydney. Established in 1982, the reference lab plays an important role in providing testing and surveillance to

monitor the changing patterns of HIV infection in Australia. Successfully implementing quality management programs in laboratories throughout the Asia Pacific region, his research interests include improving rates of HIV testing in key populations. He is the Chief Operating Officer of St Vincent's Centre for Applied Medical Research.

Professor Brian Gazzard



Professor of HIV Medicine, Imperial College, England

Brian Gazzard started the HIV unit at the Chelsea and Westminster Hospital and is now its Clinical Research Director. He qualified at Cambridge and received his MD from that institution in 1983. He was awarded the Department of Health prize for distinguished achievement in 2002 and is the chairman of the Expert Group Advising

Chief Medical Officer of Health on matters relating to HIV disease. He was awarded a CBE in 2014 for services to medicine. He is currently Professor of HIV Medicine at Imperial College London.

Dr Bridget Haire




Research Fellow, Kirby Institute, UNSW Sydney, Australia

Bridget Haire is a Research Fellow at the Kirby Institute, where she conducts research in the areas of research ethics, public health and human rights, particularly with regard to HIV and other blood-borne infections, sexual health and Ebola. She is also the President of the Australian Federation of AIDS Organisations

(AFAO), the federation for the community-based response to HIV in Australia.

Professor Anthony Kelleher



Program Head, Kirby Institute, UNSW Sydney, Australia

Tony Kelleher is an Immunologist and Immunopathologist at St Vincent's Hospital and Head of the Immunovirology and Pathogenesis program at the Kirby Institute. He leads the Infection Immunity and Inflammation theme and is Senior Vice Dean Research UNSW Medicine.

His research encompasses the role of T cells in

the defence against HIV and how the interaction between the virus and T cells might be manipulated to achieve long lasting drug free remission.

Dr Kerry Chant



Deputy Secretary, Population and Public Health and Chief Health Officer, NSW Health

Kerry Chant leads the Population and Public Health Division which has accountabilities for a broad portfolio of issues, including tobacco control, reduction of risk drinking and obesity, the promotion of physical activity, end of life care and organ donation. She has a particular interest in the response to HIV, hepatitis C and hepatitis B, and Aboriginal health.

Professor Basil Donovan



Program Head, Kirby Institute, UNSW Sydney, Australia

Basil Donovan is a Sexual Health and Public Health Physician, and NHMRC Practitioner Fellow. He heads the Sexual Health Program at the Kirby Institute. His research and policy interests include clinical, laboratory, and public health aspects of HIV and sexually transmissible infections; and priority populations such as gay

men, youth, sex workers, Aboriginal people, prisoners, juvenile offenders, and travellers. He is on the Board of Directors and Past President of the International Society for STD Research.

Professor Andrew Grulich



Program Head, Kirby Institute, UNSW Sydney, Australia

Andrew Grulich trained in Medicine in Adelaide, and in Epidemiology at the London School of Hygiene and Tropical Medicine. He completed his PhD on HIV-associated cancer at UNSW in 1998. He has led the HIV Epidemiology and Prevention Program at the Kirby Institute since 2002. The focus of his research is the prevention

of HIV and sexually transmitted infections in gay men. He led the Opposites Attract study, and, with David Cooper, the EPIC-NSW study.

Mr Geoff Honnor



Geoff Honnor has worked in a variety of roles across the NSW and Australian HIV community-based response for over 20 years. These included policy, treatments advocacy and gay men's prevention and health promotion positions as well as organisational leadership and governance roles. From 2007–2010 he was an HIV Senior Policy Advisor in NSW Health before undertaking a final three year contract as Director, HIV and Sexual Health at ACON, leading

the remarkable team of people who developed and launched the 'Ending HIV' community engagement and mobilisation initiative.

H. Clifford Lane, M.D.




Deputy Director, National Institute of Allergy and Infectious Diseases, USA

H. Clifford Lane, M.D., serves as the National Institute of Allergy and Infectious Diseases Deputy Director for Clinical Research and Special Projects, Director of the Division of Clinical Research, Chief of the Clinical and Molecular Retrovirology Section in the Laboratory of Immunoregulation and Clinical Director.

A native of Detroit, Michigan, Dr. Lane started his career at NIAID in 1979. When the AIDS epidemic emerged, he turned his attention to study immunopathogenic mechanisms of HIV disease and the potential role of immune based therapies. Most recently, he has helped develop a research program in West Africa in response to the 2014–2016 Ebola outbreak.

Professor Matthew Law



Program Head, Kirby Institute, UNSW Sydney, Australia

Matthew Law is Head of the Biostatistics and Databases Program at the Kirby Institute. He trained in mathematics and statistics in England, and was recruited to the Kirby Institute as a Lecturer in biostatistics by David Cooper in 1994. He subsequently completed his PhD at UNSW supervised by John Kaldor. Matthew has

broad research interests using biostatistical and mathematical models to investigate treatment outcomes and transmission prevention in HIV, HCV and STIs.

Professor Patrick Mallon




Professor of Microbial Diseases, School of Medicine, University College Dublin, Ireland

Paddy Mallon is Professor of Microbial Diseases in University College Dublin. He graduated from Queen's University Belfast and completed clinical training under David Cooper in Sydney, where he completed a PhD examining antiretroviral toxicities. In 2007, he returned to Dublin and established the HIV Molecular Research Group,

focusing on translational research into HIV, ageing and co-morbidities. He is a Regional Representative for the European AIDS Clinical Society (EACS), Deputy Chair of the EACS Comorbidities Guidelines Panel and Director of the Wellcome Trust/HRB Irish Clinical Academic Training Programme.

Dr Sarah Pett




Medical Research Council Clinical Trials Unit, Institute of Clinical Trials and Methodology, University College London, England

Sarah Pett is an Infectious Diseases Physician and Clinical Trialist. Her research career began in 2000 under the guidance of David Cooper and Sean Emery, and she led the ESPRIT, SILCAAT, START and MARCH projects between 2000–2013. In September 2013, she took up a

cross-institute post at the MRC CTU and IGH, University College London. Her current research focusses on improving HIV and TB outcomes in low and middle income country settings; stratified medicine trials for HCV; novel therapies for influenza; and long-term complications of HIV.

Dr Angie Pinto



PhD Candidate, Kirby Institute, UNSW Sydney, Australia

Angie Pinto is trained as an infectious diseases physician and clinical microbiologist and currently works as a Staff Specialist at Royal Prince Alfred hospital. Her PhD project at the Kirby Institute investigates several aspects of primary HIV infection including long term health outcomes, transmitted drug resistance and drivers of transmission.

Professor Carla Treloar



Director, Centre for Social Research in Health and Social Policy Research Centre, UNSW Sydney, Australia

Carla Treloar is the Director of the Centre for Social Research in Health and Social Policy Research Centre, UNSW Sydney. Since 2001, she has conducted social research in HIV, viral hepatitis and STIs, with a focus on people who use or inject drugs. She has been a member

of more than 50 advisory committees for government, health agencies and non-government organisations and is committed to the effective translation of research into policy and practice and to ethical and respectful conduct of research in close collaboration with affected communities.

Professor Sharon Lewin



Director, The Peter Doherty Institute for Infection and Immunity, The University of Melbourne and Royal Melbourne Hospital

Sharon Lewin is the inaugural Director of the Peter Doherty Institute for Infection and Immunity and Professor of Medicine, University of Melbourne. She is an infectious diseases physician and basic scientist. Her research focuses on understanding why HIV persists on

treatment and developing clinical trials aimed at ultimately finding a cure for HIV infection. She is an elected member of the Governing Council of the International AIDS Society representing the Asia Pacific region and co-chairs the IAS Global Advisory board for the Towards an HIV Cure strategy.

Associate Professor Gail Matthews



Kirby Institute, UNSW Sydney, Australia

Gail Matthews is Associate Professor in the Viral Hepatitis Clinical Research Program at the Kirby Institute. She also holds a clinical academic appointment in HIV, Infectious Diseases and Viral Hepatitis at St Vincent's Hospital, Sydney. She originally completed HIV specialist training in London before moving to Australia in 2002 to take up a position at the Kirby Institute, and

obtained her PhD on Therapeutic Strategies in HIV-HBV coinfection in 2009. She has a specific interest in HIV/viral hepatitis co-infection.

Professor Emeritus Praphan Phanuphak



Director, Thai Red Cross AIDS Research Centre, Bangkok, Thailand

Praphan Phanuphak is an internist, allergist and clinical immunologist. He is a Professor of Medicine at Chulalongkorn University, the Director of the Thai Red Cross AIDS Research Centre and Director of HIV-NAT (HIV Netherlands Australia Research Collaboration). He diagnosed Thailand's first two cases of AIDS in February

1985 and has been involved in HIV care and research as well as advocacy ever since. He is also a member of the Thailand National AIDS Committee and Strategic and Technical Advisory Committee of UNAIDS and WHO.

Ms Karen Price



Deputy CEO, ACON

Karen Price has 18 years' experience working at senior levels in the Australian health sector. In Federal and State Government roles, Karen has led significant health program areas including mental health, aged care, drug and alcohol and anti-doping in sport. With professional qualifications in education and health, Karen's interests are in the translation of evidence

to programs that support people living well in communities. Karen has experience as a member of governance and advisory boards, and research committees. Currently, Karen is the Deputy CEO of ACON – Australia's largest community based organisation specialising in HIV and LGBTI health.

Ms Jo Watson



Deputy Chair, Pharmaceutical Benefits Advisory Committee, Office of Health Technology Assessment, Australian Department of Health

Jo Watson has been involved in the Australian HIV community response since the early nineties, working with Positive Life NSW, and the National Association of People living with HIV Australia (NAPWHA) as Executive Director from 1998–2014. She is the Deputy Chair of the Consumers

Health Forum, Chair of the Commonwealth HTA Consumer Consultative Committee, and a NAPWHA Special Representative. She was appointed to the Australian Pharmaceutical Benefits Advisory Committee in 2012, and was appointed as the inaugural Deputy Chair in 2017.



Photo credit: Antonin Cermak, Fairfax Media

PROFESSOR DAVID COOPER AC

Professor David Cooper was an internationally renowned HIV clinician and researcher. He passed away in March this year. He initiated ground-breaking, collaborative infectious disease research that saved countless lives throughout the world.

His research led to the first description of the seroconversion illness, which accompanies initial HIV infection in many people. He proceeded to contribute to the development of every therapeutic drug used in HIV. He served as President of the International AIDS Society from 1994 to 1998, and during that time established the HIV Netherlands, Australia, Thailand research collaboration in Bangkok with professors Joep Lange and Praphan Phanupak. HIV-NAT is today regarded as the leading HIV research centre in South East Asia.

In June 2018, Professor Cooper was posthumously made Companion in the General Division of the Order of Australia (AC) for his service to medicine in the area of HIV/AIDS research. He was working right up to the time of his illness, running large-scale international clinical trials to improve HIV treatment, building research capacity in Indonesia and Myanmar, and leading the trial of pre-exposure prophylaxis to eliminate HIV transmission in New South Wales.

To carry forward David's legacy and vision for future infectious disease research, the David Cooper Memorial Fund has been established. Infectious diseases disproportionately affect the world's most disadvantaged communities, and David firmly advocated health as a fundamental human right in all of his endeavours. Your donation to this fund will support the research endeavours closest to David's heart: expanding access to effective infectious disease prevention and treatment.

TO DONATE TO THE FUND

kirby.unsw.edu.au/davidcooperfund

+61 2 9385 0550

